Chronic hepatitis B virus (HBV) infection is a major risk factor for developing hepatocellular carcinoma (HCC), and HBV X protein (HBx) acts as cofactor in hepatocarcinogenesis. In liver tumors from animals modeling HBx-and HBV-mediated hepatocarcinogenesis, downregulation of chromatin regulating proteins SUZ12 and ZNF198 induces expression of several genes, including epithelial cell adhesion molecule (EpCAM). EpCAM upregulation occurs in HBV-mediated HCCs and hepatic cancer stem cells, by a mechanism not understood. Herein we demonstrate HBx induces EpCAM expression via active DNA demethylation. In hepatocytes, EpCAM is silenced by polycomb repressive complex 2 (PRC2) and ZNF198/LSD1/Co-REST/HDAC1 chromatin-modifying complexes. Cells with stable knockdown of SUZ12, an essential PRC2 subunit, upon HBx expression demethylate a CpG dinucleotide located adjacent to NF-κB/RelA half-site. This NF-κB/RelA site is in a CpG island downstream from EpCAM transcriptional start site (TSS). Chromatin immunoprecipitation (ChIP) assays demonstrate HBx-dependent RelA occupancy of NF-κB half-site, whereas RelA knockdown suppresses CpG demethylation and EpCAM expression. Tumor necrosis factor-α activates RelA, propagating demethylation to nearby CpG sites, shown by sodium bisulfite sequencing. RelA-dependent demethylation occurring upon HBx expression requires methyltrasferase EZH2, TET2 a key factor in cytosine demethylation and inactive DNMT3L, shown by knockdown assays and sodium bisulfite sequencing. Co-immunoprecipitations and sequential ChIP assays demonstrate that RelA in the presence of HBx forms a complex with EZH2, TET2 and DNMT3L, although the role of DNMT3L remains to be understood. Interestingly, the human EpCAM gene also has a CpG island downstream from its TSS, and a NF-κB-binding site flanked by CpGs. HepG2 cells derived from human HCC exhibit demethylation of these NF-κB-flanking CpG sites, and HBV replication propagates demethylation to nearby CpG sites. DLK1, another PRC2 target gene, also upregulated in HBV-mediated HCCs, is demethylated in liver tumors at CpG dinucleotides flanking the NF-κB-binding sequence, supporting that this active DNA demethylation mechanism functions during oncogenic transformation.
INTRODUCTION
Chronic infection by the hepatitis B virus (HBV) is linked to hepatocellular carcinoma (HCC). 1 The multifunctional HBV X protein (HBx) encoded by HBV 2, 3 is essential for the viral life cycle, 4 and implicated in HCC pathogenesis acting as a cofactor in hepatocarcinogenesis 5, 6 by a mechanism not well understood. Regarding this mechanism, our earlier studies 7-9 used a genome-wide short hairpin RNA library screen and identified downregulation of SUZ12 and ZNF198 proteins has role in HBxmediated oncogenic transformation. 4 SUZ12 is a component of the polycomb repressive complex 2 (PRC2), comprises essential subunits EZH2, SUZ12 and EED, which mediates the repressive trimethylation of H3 on lysine 27.
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LSD1/Co-REST/HDAC1 complex, stabilized by ZNF198, 11 erases activating histone modifications, namely methylations of H3 on lysine 4 and acetylations. Moreover, the repressive chromatinmodifying activity of these two complexes is coupled by binding the long noncoding RNA HOTAIR. 12 In animal models of HBx-and HBV-mediated hepatocarcinogenesis, downregulation of ZNF198 and/or SUZ12 in liver tumors is associated with elevated expression of a subset of SUZ12/PRC2 target genes including the epithelial cell adhesion molecule (EpCAM). 13 EpCAM expression characterizes both bi-potential liver progenitors 14, 15 and hepatic cancer stem cells. 16 Here, we investigate the mechanism of EpCAM gene reactivation, using an immortalized mouse liver cell line expressing HBx via the Tet-off expression system, 17 in combination with stable knockdown cell lines of SUZ12 and ZNF198. 9 EpCAM is a 40 kDa transmembrane protein highly expressed in most epithelial cancers. 18, 19 The elevated expression of EpCAM in rapidly proliferating tumor cells, together with its role in the activation of Wnt signaling, 20, 21 and the enhanced expression of c-myc and cyclins, 22, 23 support a role for EpCAM in tumor progression and cancer-initiating/stem cells. 24 However, despite the frequent and elevated expression of EpCAM in tumors and cancer-initiating cells, the molecular mechanism mediating EpCAM transcription is not understood. In Hep3B cells, Wnt/β-catenin signaling was shown to upregulate EpCAM-luciferase reporter expression. 16 In human ovarian cancer cell lines, EpCAM expression was correlated with changes in DNA methylation and histone modifications, 25 and in human embryonic stem cells the EpCAM gene was identified as a PRC2 target. 26 Our studies also identified EpCAM expression to be epigenetically silenced by the PRC2 and LSD1/Co-REST/HDAC1 chromatin-modifying complexes in untransformed hepatocytes. 13 Another epigenetic mechanism directly involved in regulating transcription is DNA methylation of cytosine residues at CpG dinucleotides, generating 5-methylcytosine. 27 This epigenetic modification is mediated by de novo DNA methyltransferases DNMT3A and DNMT3B, and propagated to daughter cells during DNA replication by the maintenance enzyme DNMT1. 28 The DNMT3 family also includes the catalytically inactive DNMT3L. In embryonic stem cells, DNMT3L activates DNA methylation at gene bodies and suppresses DNA methylation at promoters of bivalent genes. 29 DNA demethylation also has a crucial role in activation of silenced genes. The ten-eleven translocation (TET) enzymes, TET1, TET2 and TET3 catalyze oxidation of 5-methylcytosine to hydroxylated 5-hydroxymethylcytosine form, leading to cytosine demethylation. 30 Recent studies have identified direct interaction of TETs with specific transcription factors as a mechanism for targeting demethylation of specific cytosine residues, referred to as active DNA demethylation. [31] [32] [33] Herein, we demonstrate that EpCAM transcription is dependent on cellular context. In SUZ12 knockdown cells expressing HBx, a CpG site located in proximity to an A/T-centric NF-κB half-site, 34 downstream from the transcriptional start site (TSS) of EpCAM, becomes demethylated. This demethylation is necessary for EpCAM expression. We show EpCAM expression by HBx requires the transcription factor RelA, the methyltransferase EZH2, the TET2 enzyme catalyzing the conversion of 5-methylcytosine to 5-hydroxymethylcytosine and the catalytically inactive DNMT3L. Although the role of DNMT3L in this complex is not understood, we interpret these results to mean that RelA binds specifically to the NF-κB half-site, 5'-GGGAAT-3', 35, 36 and via interaction with EZH2, recruits TET2 and DNMT3L to the EpCAM sequence. Thus, our results identify a novel mechanism of active DNA demethylation, directed by RelA binding to its half-site.
RESULTS
PRC2 and LSD1/Co-REST/HDAC1 complexes coordinately regulate activity of the EpCAM promoter Our earlier studies observed a correlation between loss-of-function of PRC2 and LSD1/Co-REST/HDAC1 chromatin-modifying complexes and EpCAM expression in liver tumors of animals modeling HBx-and HBV-mediated hepatocarcinogenesis. 13 To understand the molecular mechanism deregulating EpCAM expression in HBx-and HBV-mediated HCCs, we used the tetracycline-regulated HBx-expressing 4pX-1 GIPZ cell line, 17 derived from the immortalized mouse hepatocyte AML12 cell line, 37 and knockdown cell lines for SUZ12 and ZNF198, namely 4pX-1-SUZ12 kd and 4pX-1-ZNF198 kd , described earlier 4 (Supplementary Figure S1A) . Indeed, EpCAM expression exhibited HBx-dependent induction and enhanced expression in SUZ12 and ZNF198 knockdown cell lines (Supplementary Figure S1B) .
To directly link regulation of EpCAM expression to PRC2 and LSD1/Co-REST/HDAC1 complexes, first, we examined the effect of knockdown of long noncoding RNA HOTAIR known to tether together these complexes. 12 HOTAIR knockdown in 4pX-1 GIPZ cells increased EpCAM mRNA by nearly 10-fold (Figure 1a) , whereas in 4pX-1-SUZ12 kd and 4pX-1-ZNF198 kd cells the increase was only twofold and fourfold, respectively (Figure 1a) . EpCAM immunoblots and flow cytometry with EpCAM antibody of HBx-expressing 4pX-1 GIPZ cells further confirm EpCAM induction by HOTAIR knockdown (Figures 1b and c ). To further demonstrate coordinated effects of PRC2 and LSD1/Co-REST/ HDAC1 complexes on the EpCAM promoter, we performed chromatin immunoprecipitation (ChIP) assays with antibodies for H3K27me3 and H3K4me1 using 4pX-1-SUZ12 kd and 4pX-1-ZNF198 kd cell lines. HBx expression had no effect on the association of H3 with the EpCAM promoter. However, the histone modifications of the EpCAM promoter in the SUZ12 and ZNF198 knockdown cell lines exhibited an HBx-dependent increase in the activating modification H3K4me1, and a reduction of the repressive modification H3K27me3, in comparison with 4pX-1 GIPZ cells (Figure 1d and Supplementary Figure S2) . Together, these results support the PRC2 and LSD1/Co-REST/HDAC1 complexes coordinately regulate histone modifications of the EpCAM promoter.
HBx induces DNA demethylation of EpCAM CpG sites in a cell context-dependent manner As histone modifications correlate with DNA methylation of CpG sites in gene regulatory sequences, [38] [39] [40] and the PRC2 complex interacts with DNMTs, 41 we examined whether DNA methylation regulates EpCAM expression. Indeed, treatment with 5-Aza-2-deoxycytidine, an inhibitor of DNMTs enhanced EpCAM expression (Supplementary Figure S3A) . Furthermore, quantification of the levels of 5-hydroxymethylcytosine of the EpCAM sequence by hydroxymethylated DNA immunoprecipitation assays demonstrated an increase in cytosine hydroxymethylation by HBx in 4pX-1 GIPZ and 4pX-1-SUZ12 kd cells (Supplementary Figure S3B) , suggesting that active DNA demethylation regulates EpCAM expression.
Next, we used sodium bisulfite sequencing to investigate effects of SUZ12 and ZNF198 knockdown on the DNA methylation pattern of the EpCAM gene. Using the Methprimer program, we identified a CpG island comprising 12 CpG dinucleotides downstream from the TSS of EpCAM (Figure 2a ). Sodium bisulphite treatment of DNA from 4pX-1 GIPZ cells (Figure 2b ) and 4pX-1-ZNF198 kd cells (Figure 2c ) showed the DNA methylation pattern of the 12 CpG dinucleotides did not exhibit significant change because of HBx expression. Interestingly, in SUZ12 knockdown cells (Figure 2d ) an HBx-dependent demethylation was observed at CpG dinucleotide #10, in nearly 90% of sequenced clones. CpG site #10 is adjacent to an A/T-centric RelA half-site. 34 Earlier X-ray crystallographic studies of the RelA homodimer demonstrated its binding to the A/T-centric half-site. 34 RelA together with EZH2 regulate EpCAM expression in SUZ12 knockdown cells To determine whether DNA demethylation of CpG site #10, located in proximity to an A/T-centric RelA half-site, 34 is functional in EpCAM expression, first, we examined by ChIP assays whether RelA binds to the EpCAM sequence spanning the 12 CpG sites. In 4pX-1-SUZ12 kd cells, HBx increased by nearly 50% the occupancy of the EpCAM CpG island by RelA ( Figure 3a) . Next, we knockeddown RelA by small interfering RNA (siRNA) transfection in 4pX-1-SUZ12 kd cells and monitored EpCAM expression by PCR. We observed a fivefold reduction in EpCAM mRNA levels by RelA knockdown, supporting the functional significance of RelA in EpCAM transcription (Figure 3b ). By contrast, RelA knockdown in 4pX-1-ZNF198
kd cells resulted only in 1.5-fold decrease in EpCAM mRNA levels (Supplementary Figure S4) .
Recent studies have shown direct interaction of EZH2 with RelA/ RelB heterodimer in promoting expression of NF-κB targets in breast cancer. 42 Therefore, we investigated whether EZH2 has a similar role in EpCAM expression. We determined EZH2 protein levels in the three cell lines 26 as a function of HBx expression. Interestingly, HBx increased protein level of EZH2 in all three cell lines ( Figure 3c ). Next, we examined by ChIP assays association of EZH2 with the EpCAM sequence containing the RelA half-site. In 4pX-1-SUZ12 kd cells, EZH2 exhibited enhanced occupancy at the EpCAM sequence ( Figure 3d) ; by contrast absence of SUZ12 occupancy at that site ( Figure 3d ) suggests that EZH2 interacts alone, not in complex with the other subunits of PRC2. Reciprocal co-immunoprecipitations of RelA and EZH2 demonstrate that these proteins interact with each other (Figure 3e ), in agreement with similar observations by others. 42 To determine whether association of RelA and EZH2 with the EpCAM sequence has functional significance, we knocked-down EZH2 and quantified by PCR EpCAM mRNA levels. In 4pX-1-SUZ12 kd cells, transfection of EZH2 siRNA reduced expression of EpCAM (Figure 3f ), thereby demonstrating that the interaction between RelA and EZH2 ( Figure 3e ) is functionally important for EpCAM expression.
TET2 and DNMT3L are required for DNA demethylation of EpCAM The HBx-dependent demethylation of CpG dinucleotide #10, observed selectively in SUZ12 knockdown cells, suggested an active DNA demethylation mechanism. To investigate this mechanism, we determined by PCR mRNA levels of enzymes involved in DNA demethylation. The dioxygenases TET1-3 directly convert 5-methylcytosine to 5-hydroxymethylcytosine. 43, 44 On the other hand, the catalytically inactive DNMT3L indirectly maintains low levels of DNA methylation at gene promoters/regulatory sequences by displacing DNMT3A and DNMT3B from binding the PRC2 complex.
29 TET1 45 and DNMT3L 29 were reported to interact with EZH2. However, whether TET2 and TET3 enzymes interact with EZH2 is unknown. and d) . As TET2 lacks the CXXC motif required for DNA binding, present in TET1 and TET3, 30 we reasoned TET2 may interact with the RelA/EZH2 complex (Figure 3e ). Therefore, we knocked-down TET2 in 4pX-1-SUZ12 kd cells by siRNA transfection and quantified expression levels of EpCAM. Knockdown of TET2 in the presence of HBx significantly reduced EpCAM expression in 4pX-1-SUZ12 kd cells (Figure 4e ). By contrast, siRNA knockdown of TET3 had no effect on EpCAM mRNA levels (Supplementary Figure S5C) . Also, knockdown of DNMT3L by siRNA transfection reduced EpCAM expression in 4pX-1-SUZ12 kd cells (Figure 4f ).
TET2 and DNMT3L are in complex with EZH2 and RelA in HBx-expressing cells Next, we examined whether RelA, EZH2, DNMT3L and TET2 are in complex ( Figure 5 ). Indeed, RelA co-immunoprecipitated DNMT3L and EZH2, whereas expression of HBx enhanced the amount of co-immunoprecipitated EZH2 and TET2 (Figure 5a ). Conversely, TET2 co-immunoprecipitated EZH2, and in the presence of HBx we detected increased levels of TET2, RelA and DNMT3L (Figure 5b ). In turn, DNMT3L co-immunoprecipitated EZH2 and RelA, whereas HBx expression increased the amount of co-immunoprecipitated EZH2 and TET2 (Figure 5c ). Importantly, this complex comprises RelA, EZH2, TET2 and DNMT3L does not contain SUZ12, because immunoprecipitation of SUZ12 does not co-immunoprecipitate these proteins (Figure 5d ). To demonstrate the functional assembly of the RelA-directed EZH2/TET2/DNMT3L complex, we used two approaches (Figures 5e and f) . First, we performed ChIP assays with the RelA antibody and sequential ChIP assays (SeqChIP) with antibody for TET2, DNMT3L and EZH2. HBx expression in 4pX-1-SUZ12 kd cells increased the association of TET2, DNMT3L and EZH2 with RelA-bound to the EpCAM CpG island (Figure 5e ). Conversely, siRNA knockdown of RelA reduced the amount of TET2, DNMT3L and EZH2 that immunoprecipitated in ChIP assays with the EpCAM sequence (Figure 5f ). Taken together, these results show the requirement for RelA in the formation of the EZH2/TET2/DNMT3L complex, and the association of these proteins with the EpCAM chromatin. TNF-α treatment and HBV replication propagate DNA demethylation to additional CpG sites in proximity to the RelA/NF-κB site To confirm the role of RelA in demethylation of the EpCAM sequence, we activated RelA by treatment with tumor necrosis factor-α (TNF-α; 0.1 ng/ml), in HBx-expressing cells transfected with EZH2. Although HBx activates NF-κB signaling, 46 we reasoned treatment with TNF-α will further increase or prolong RelA activation. Indeed, under these conditions, EpCAM expression was further elevated (Figure 7a) . Interestingly, sodium bisulfite sequencing detected DNA demethylation of additional CpG sites, sites #3, 4, 6 and 9 (Figure 7b) , supporting that the level/duration of RelA activation influences demethylation of additional CpG sites.
To link these findings to the regulation of the human EpCAM promoter, we determined by sodium bisulfite sequencing the methylation pattern of a 450-bp sequence downstream from the TSS of the human EpCAM gene, containing 61 CpG dinucleotides (Figure 8a) . Interestingly, CpG site #23 is adjacent to an NF-κB site (Figure 8a ). We used a human liver cancer cell line derived from HepG2 cells, named HepAD38 cell line. 47 HepAD38 cells support Active DNA demethylation via RelA/EZH2/TET2 complex H Fan et al HBV replication via the stable integration of the HBV genome under control of the tetracycline-regulated (Tet-off) expression system. 47 Under conditions of HBV replication by tetracycline removal, monitored by the increased protein levels of the viral HBc antigen (Figure 8b ), EpCAM expression increases, 13 SUZ12 levels decreased, 13 whereas EZH2 levels increased (Figure 8b ). In turn, the downregulation of SUZ12 and ZNF198 proteins observed in HBV replicating cells resulted in reduction of the repressive H3K27me3 modification, whereas H3K4 modifications associated with transcriptional activation were increased (Figure 8c ). ChIP assays show reduction of the repressive H3K27me3 associated with the EpCAM promoter as a function of HBV replication (Figure 8d ). In agreement with the tumor origin of this cell line, sodium bisulfite sequencing showed that CpG site #23 was unmethylated. Interestingly, upon induction of HBV replication for 2 days, additional CpG sites became demethylated (Figure 8e) , as with EZH2 overexpression and TNF-α treatment in 4pX-1-SUZ12 kd cells, suggesting that active DNA demethylation is involved in the expression of the human EpCAM gene, in HBV replicating cells.
In further support of this mechanism, we re-analyzed the HCC transcriptome data of Boyault et al., 48 which classified HCCs in six subgroups (G1-G6). Of interest is the G1 group of tumors associated with low copy number of HBV and overexpression of genes expressed in fetal liver. Indeed, the G1 group exhibits robust expression of hepatic progenitor genes EpCAM and DLK1 49 ( Figure 9a and Supplementary Table S1), both genes are targets of the PRC2 and LSD1/Co-REST/HDAC1 complexes. The G1 group also exhibits a small but statistically significant induction of EZH2 and RelA (Figure 9a and Supplementary  Table S1 ), key factors in our mechanism of active DNA demethylation ( Figure 6 ).
To evaluate the methylation status of the EpCAM CpG island under study (Figure 8a ) in human HCCs, we examined the methylation data (Illumina Human Methylation 450 array) from The Cancer Genome Atlas (TCGA), by evaluating the beta value (β) defined as the ratio of intensities between methylated vs nonmethylated DNA. However, beta values for the EpCAM CpG island under study are not represented in TCGA data. As DLK1 is also overexpressed in the G1 group of HCCs, and is the target of PRC2 and LSD1/Co-REST/HDAC1 complexes, 13 we examined the DNA methylation status of CpG sites located within NF-κB-binding sites. Using TCGA human HCC methylome, we identified in the DLK1 promoter a CpG dinucleotide within an NF-κB-binding site. Importantly, beta values indicate that indeed this CpG site is demethylated in human HCCs in comparison with peritumoral tissue (Figure 9b ). We interpret these data to mean that the DNA demethylation mechanism we identified in our model cell lines is also functional in human HCCs.
DISCUSSION
In this study, we provide evidence for a novel mechanism of active DNA demethylation induced by HBx that allows re-expression of the EpCAM gene observed in HBV-mediated HCCs. 13 We demonstrate that this mechanism is directed by the transcription factor RelA. RelA binds to an A/T-centric RelA half-site 35, 36 located downstream from the TSS of the EpCAM gene (mouse and human) and directs DNA demethylation by TET2. Our results identify a novel bridging function for EZH2 in the formation of the DNA demethylation complex comprising TET2 and the catalytically inactive DNMT3L. Although in this study, we have not determined the mechanism by which DNMT3L functions in this complex, studies by others have shown that DNMT3L maintains the demethylated state in bivalent promoters in embryonic stem cells. Specifically, although DNMT3L enhances DNA methylation at gene bodies of active genes, it prevents DNA methylation at the promoters of H3K27me3-positive genes, like EpCAM. Our results show that DNMT3L interacts directly with EZH2 and TET2. We speculate that following DNA demethylation, DNMT3L, recruited to the EpCAM promoter via the RelA complex, counteracts the activity of DNMT3A and DNMT3B, thereby maintaining hypomethylation. Importantly, we demonstrate this DNA demethylation complex is induced by HBx in the context of SUZ12 downregulation, that is, EZH2 acts independently of the other core subunits of the PRC2 complex (Figures 3d and 5d) . The cellular context of the 4pX-1-SUZ12 kd cell line resembles downregulation of SUZ12 observed in liver tumors of animals modeling HBx-and HBV-mediated hepatocarcinogenesis, as well as the host cell during HBV replication 13 (Figure 8b ), all of which exhibit elevated expression of EpCAM. 13 Our recent studies (Zhang et al) 50 have determined the mechanism by which HBx promotes SUZ12 downregulation, involving proteasomal degradation induced by Polo-like kinase 1-mediated phosphorylation of SUZ12. In turn, Polo-like kinase 1 is overexpressed in many human cancers including HBV-induced HCC, and is activated by HBx. 7 How HBx induces formation of the RelA-directed DNA demethylation complex is not understood. RelA undergoes posttranslational modifications including methylation. 51 Whether EZH2 methylates RelA or other members of the complex remains to be determined. Based on recent findings that RelA activity is regulated by methylation, 51 and by analogy to the ability of EZH2 to methylate the transcription factor STAT3, 52 it is reasonable to propose that EZH2 is a likely methyltransferase for RelA. HBx could alter the methyltransferase specificity of EZH2 by inducing its phosphorylation, as it has been shown to occur for the EZH2-mediated methylation of STAT3. 52 It is well-documented that HBx induces activation of cellular signal transduction pathways, 2, 3 as well as activation of the mitotic Polo-like kinase 1. 7 Interestingly, EZH2 contains several Polo-like kinase 1 consensus phosphorylation sites. We speculate HBx-driven posttranslational modifications of EZH2 alter its methyltransferase specificity toward methylation of RelA or the other components of the DNA demethylation complex.
The involvement of RelA in this active DNA demethylation process is quite interesting, because RelA/NF-κB is constitutively activated in many human cancers including liver cancer. 53 HBx, 45 as well as inflammatory stimuli originating from the microenvironment, 53 activates NF-κB. Our results showing propagation of DNA demethylation to nearby CpG sites in the EpCAM gene upon treatment of HBx-expressing cells with TNF-α, identify another mechanism by which chronic inflammation could be involved in cancer pathogenesis. We speculate RelA/ NF-κB, activated by HBx and TNF-α secreted by cytotoxic T lymphocytes, 54 integrates effects of chronic inflammation and HBx action in mediating HCC pathogenesis in chronically infected HBV patients. Furthermore, recent studies have shown that an inverse relationship exists between enhanced RelA expression and decreased HNF4 expression in human liver tumors, 55 thereby linking RelA expression to less differentiated HCCs exhibiting elevated expression of EpCAM. 16 Although NF-κB regulates various classes of genes involved in tumor development, including proliferation, survival and metastasis, 53 the repertoire of genes regulated via this active DNA demethylation mechanism directed by RelA and EZH2 requires further studies. Our results have identified the hepatic progenitor DLK1, another PRC2 target gene, to be demethylated in human HCCs at a CpG site located within NF-κB cis-acting element (Figure 9b ). Other genes that could undergo a similar DNA demethylation mechanism include the PRC2 target gene BAMBI, 13 or genes expressed in early hepatic progenitors or during hepatic lineage determination such as SOX9 56 and SALL4. 57 Interestingly, these genes have CpG sites located within NF-κB cis-acting elements. Further studies are needed to determine the mechanism by which this active DNA demethylation, associated with the NF-κB cis-acting elements, regulates transcription.
Regarding the involvement of EZH2 in this DNA demethylation mechanism, our results show that EZH2 acts independently of the other subunits of the PRC2 complex (Figure 5d ). Whether the methyltransferase activity of EZH2 is required for its involvement in the RelA-driven DNA demethylation is also unknown. As EZH2 is overexpressed in many human cancers including liver cancer, 58 our studies identify a novel role for EZH2, independent of its histone3 methyltransferase function, in oncogenesis.
MATERIALS AND METHODS

Cell lines
The 4pX-1 cell line is a tetracycline-regulated HBx-expressing cell line, derived from immortalized mouse hepatocyte AML12 cells. 37 4pX-1 GIPZ is derived from the 4pX-1 cell line 17 containing a stable insertion of GIPZ vector and thus serving as vector control for the stable knockdown (kd) cell lines 4pX-1-SUZ12 kd and 4pX-1-ZNF198 kd . All 4pX-1-derived cell lines express HBx by tetracycline removal for 18 h and grown as described. 9, 17 HBx expression is confirmed by reverse transcriptase-PCR. Treatment of indicated cell lines with 10 μM 5-aza-2'-deoxycytidine (11166, Cayman Chemical, Ann Arbor, MI, USA) was for 48 h. The HepAD38 cell line that supports HBV replication by removal of tetracycline was grown as described. 47 Sodium bisulfite sequencing Sodium bisulfite sequencing used the following reagents and protocols described by the manufacturers: PureLink Genomic DNA Mini Kit (K1820-01, Invitrogen, Grand Island, NY, USA) for genomic DNA isolation; EZ DNA Methylation-Direct Kit (D5020, Zymo, Irvine, CA, USA) for bisulfate treatment of DNA. Mouse EpCAM bisulfate sequencing primers were designed by Methprimer. 59 ChIP assays, immunoprecipitations and immunoblot ChIP assays, immunoprecipitations and immunoblot analyses were performed using standard protocols. 13 The following reagents and antibodies were used: lysis buffer (9803, Cell Signaling, Danvers, MA, USA); 
